Has Emily Guerard, MD received payments from drug or device companies?

Yes. Drug and device makers reported $276,496 in general payments to Emily Guerard, MD across 305 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Emily Guerard, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Emily Guerard, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Emily Guerard, MD

Hematology & Oncology · Reno, NVNPI 1417190414

Payments from drug & device makers

$276,496in general payments, 2019–2025

Across 305 payments — averaging $906.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$113K
Puma Biotechnology, Inc.$93K
Boehringer Ingelheim Pharma GmbH & Co.kg$62K
Boehringer Ingelheim International GmbH$2K
E.r. Squibb & Sons, L.L.C.$504
AstraZeneca$437
plus $6K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	20	$113,450
Puma Biotechnology, Inc.	12	$92,577
Boehringer Ingelheim Pharma GmbH & Co.kg	8	$61,744
Boehringer Ingelheim International GmbH	7	$1,872
E.r. Squibb & Sons, L.L.C.	20	$504
AstraZeneca(2 entities)	17	$437
Merck	15	$332
Incyte Corporation	11	$321
Genentech USA, Inc.	9	$305
Pfizer	13	$299
Daiichi Sankyo Inc.	11	$245
Bristol Myers Squibb	6	$241
Johnson & Johnson	11	$233
Regeneron Healthcare Solutions, Inc.	7	$212
Novartis	10	$209
Tersera Therapeutics LLC	6	$175
Amgen	6	$165
Sanofi	5	$160
AbbVie	3	$152
Spectrum Pharmaceuticals Inc.	1	$148
Epizyme, Inc.	2	$136
Beigene USA, Inc.	2	$128
Takeda Pharmaceuticals U.S.A., Inc.	6	$126
Astellas Pharma US Inc	5	$123
Pharmaessentia USA Corporation	4	$119
Eisai Inc.	4	$117
Blueprint Medicines Corporation	1	$107
GSK	4	$98
Mirati Therapeutics, Inc.	4	$91
Pharmacyclics LLC, An Abbvie Company	4	$91
Springworks Therapeutics, Inc.	3	$90
Gilead(2 entities)	4	$89
EMD Serono, Inc.	4	$87
Servier Pharmaceuticals LLC	4	$81
Kyowa Kirin, Inc.	3	$79
Seagen Inc.	4	$75
Ipsen Biopharmaceuticals, Inc	3	$74
Acrotech Biopharma Inc.	4	$64
Jazz Pharmaceuticals Inc.	3	$57
Array Biopharma Inc	2	$57
Exelixis Inc.	2	$56
Octapharma USA, Inc.	3	$53
ADC Therapeutics America, Inc.	2	$53
Deciphera Pharmaceuticals Inc.	2	$53
Sumitomo Pharma America, Inc.	2	$46
Taiho Oncology, Inc.	2	$44
Sobi, Inc	2	$42
Bayer	2	$41
Morphosys, US Inc.	2	$39
Stemline Therapeutics Inc.	1	$34
AVEO Pharmaceuticals, Inc.	1	$30
Verity Pharmaceuticals Inc.	1	$28
Secura Bio, Inc.	1	$26
Shire North American Group Inc	1	$24
Sun Pharmaceutical Industries Inc.	1	$24
Karyopharm Therapeutics Inc.	1	$24
Apellis Pharmaceuticals, Inc.	1	$24
Heron Therapeutics, Inc.	1	$23
Organon	1	$22
Agios Pharmaceuticals, Inc.	1	$22

How this compares

$276,496 in reported general payments places this provider in the 75th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$4,190,820

Medicare patients

738

Services billed

146,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →